Caristo has been supporting multiple pharmaceutical and biotech companies’ development efforts by leveraging our capabilities in assessing coronary inflammation, plaque, and radiotranscriptomic profiling.
Caristo can support both pre-clinical and clinical stage drug trials, including:
Agepha Pharma, a leading multinational pharmaceutical company with the first FDA-approved anti-inflammatory cardiovascular treatment (LODOCO®-- colchicine, 0.5 mg tablets), announced that they will collaborate with Caristo to improve awareness and clinical education about the central role of inflammation in coronary artery disease.
Read Press Release
Abcentra LLC, a clinical-stage biopharmaceutical company partnered with Caristo Diagnostics to leverage CaRi-Heart AI technology to measure changes in patients’ coronary artery inflammation as a result of therapeutic intervention using Orticumab a monoclonal antibody. CaRi-Heart predicted a 50% reduction in risk of fatal cardiac events...
Read Press ReleaseInterested in collaborating with us?
Get in touch with the Caristo Team here
